Works matching DE "PHARMACOLOGY periodicals"
2
- Diabetes, Obesity & Metabolism, 2019, v. 21, p. 1, doi. 10.1111/dom.13705
- Article
3
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 4, p. i, doi. 10.1111/dom.13540
- Ruz‐Maldonado, Inmaculada;
- Pingitore, Attilio;
- Liu, Bo;
- Atanes, Patricio;
- Huang, Guo Cai;
- Persaud, Shanta J.;
- Baker, David;
- Alonso, Francisco José;
- Bermúdez‐Silva, Francisco Javier
- Article
4
- 2018
- Franklin, Zara J.;
- Tsakmaki, Anastasia;
- Fonseca Pedro, Patricia;
- King, Aileen J.;
- Huang, Guo Cai;
- Amjad, Sakeena;
- Persaud, Shanta J.;
- Bewick, Gavin A.
- Cover Art
5
- Diabetes, Obesity & Metabolism, 2018, v. 20, p. 1, doi. 10.1111/dom.13404
- Article
6
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 11, p. 1051, doi. 10.1111/dom.12567
- Article
7
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 12, p. 2591, doi. 10.1111/bcp.13116
- Article
8
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 2, p. 217, doi. 10.1111/bcp.13106
- Article
9
- British Journal of Clinical Pharmacology, 2016, v. 81, n. 4, p. 579, doi. 10.1111/bcp.12767
- Article
11
- 2014
- Somogyi, Andrew A.;
- Lewis, Lionel D.;
- Cohen, Adam F.;
- Flockhart, David A.;
- Ferro, Albert;
- Loke, Yoon K.;
- Ritter, James M.
- Editorial
12
- Critical Reviews in Toxicology, 2016, v. 46, n. 10, p. 917, doi. 10.1080/10408444.2016.1227524
- Article
13
- Drug Development Research, 2018, v. 79, n. 4, p. i, doi. 10.1002/ddr.21361
- Article
14
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 6, p. 523, doi. 10.1002/pds.792
- Article
15
- International Journal of Neuropsychopharmacology, 2014, v. 17, n. 5, p. f1, doi. 10.1017/S1461145714000170
- Article
16
- International Journal of Neuropsychopharmacology, 2012, v. 15, n. 8, p. f1, doi. 10.1017/S1461145712000855
- Article
18
- European Review for Medical & Pharmacological Sciences, 2012, v. 16, n. 11, p. 1461
- Article
19
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 260, doi. 10.1002/cpdd.661
- Article
20
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 133, doi. 10.1002/cpdd.590
- Article
21
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 1, p. 1, doi. 10.1002/cpdd.398
- Article
22
- Neuropsychobiology, 2015, v. 71, n. 4, p. I, doi. 10.1159/000439317
- Article
23
- Neuropsychobiology, 2015, v. 71, n. 4, p. X, doi. 10.1159/000440744
- Article
24
- Canadian Journal of Physiology & Pharmacology, 2012, v. 90, n. 6, p. iii, doi. 10.1139/y11-126
- Clanachan, Alexander A.S.C.;
- Smith, Peter A.
- Article
25
- Canadian Journal of Physiology & Pharmacology, 2010, v. 88, n. 2, p. -1, doi. 10.1139/y10-900
- Article
26
- Indian Journal of Pharmacology, 2017, v. 49, n. 1, p. 1, doi. 10.4103/ijp.IJP_47_17
- Article
27
- Pharmacotherapy, 2017, v. 37, n. 12, p. 1485, doi. 10.1002/phar.1821
- Article
29
- 2012
- Kojima, Taro;
- Higashi, Kenjirou;
- Suzuki, Toyofumi;
- Tomono, Kazuo;
- Moribe, Kunikazu;
- Yamamoto, Keiji
- Correction Notice
30
- Acta Pharmacologica Sinica, 2015, v. 36, n. 4, p. iii, doi. 10.1038/aps.2015.13
- Article
31
- Acta Pharmacologica Sinica, 2015, v. 36, n. 2, p. 289, doi. 10.1038/aps.2015.1
- Article
32
- Acta Pharmacologica Sinica, 2015, v. 36, n. 2, p. 290, doi. 10.1038/aps.2015.2
- Article
33
- Pharmacology Research & Perspectives, 2016, v. 4, n. 1, p. n/a, doi. 10.1002/prp2.182
- Article
34
- 2015
- Curtis, Michael J.;
- Abernethy, Darrell R.
- Editorial
35
- Journal of Medical Toxicology, 2010, v. 6, n. 1, p. 3, doi. 10.1007/s13181-010-0026-5
- Article
36
- Human Psychopharmacology: Clinical & Experimental, 2014, v. 29, n. 1, p. i, doi. 10.1002/hup.2353
- Article
37
- Pharmacology, 2011, v. 88, n. 5/6, p. I, doi. 10.1159/000335173
- Article
38
- Pharmacology, 2011, v. 88, n. 5/6, p. 349, doi. 10.1159/000335171
- Article
39
- Cardiology, 2014, v. 127, n. 2, p. X, doi. 10.1159/000359978
- Article
40
- Cardiology, 2013, v. 124, n. 4, p. X, doi. 10.1159/000351501
- Article
41
- Basic & Clinical Pharmacology & Toxicology, 2019, v. 124, p. 380, doi. 10.1111/bcpt.13218
- Article
42
- Basic & Clinical Pharmacology & Toxicology, 2019, v. 124, n. 4, p. 349, doi. 10.1111/bcpt.13064
- Article
43
- Basic & Clinical Pharmacology & Toxicology, 2019, p. 120, doi. 10.1111/bcpt.13174
- Article
44
- Basic & Clinical Pharmacology & Toxicology, 2019, v. 124, n. 1, p. 1, doi. 10.1111/bcpt.13061
- Article
45
- Basic & Clinical Pharmacology & Toxicology, 2018, v. 123, p. 1, doi. 10.1111/bcpt.13158
- Article
46
- Basic & Clinical Pharmacology & Toxicology, 2018, v. 122, n. 6, p. 537, doi. 10.1111/bcpt.12887
- Article
47
- Basic & Clinical Pharmacology & Toxicology, 2017, v. 121, p. 1, doi. 10.1111/bcpt.12812
- Article
48
- Basic & Clinical Pharmacology & Toxicology, 2017, v. 120, n. 2, p. 103, doi. 10.1111/bcpt.12732
- Article
49
- Basic & Clinical Pharmacology & Toxicology, 2016, v. 119, p. 1, doi. 10.1111/bcpt.12645
- Article
50
- Basic & Clinical Pharmacology & Toxicology, 2016, v. 119, n. 6, p. 521, doi. 10.1111/bcpt.12470
- Article